Enadenotucirev is under clinical development by Akamis Bio and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Squamous Non-Small Cell Lung Cancer have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Enadenotucirev’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Enadenotucirev overview

Enadenotucirev (ColoAd1) is under development for the treatment of solid tumors including metastatic bladder cancer, salivary gland cancer, fallopian tube cancer, squamous and non-squamous non-small cell lung cancer, primary peritoneal cancer, colon cancer, urothelial cell carcinoma, head and neck cancer squamous cell carcinoma, advanced epithelial tumor. It is administered through intratumoral, intravenous and intraperitoneal routes. It is a chimeric oncolytic vaccine consists of chimeric group B adenovirus (11p/3) with deletions in the E3 and E4 regions. It was also under development for metastatic colorectal cancer, breast cancer, platinum resistant ovarian cancer, renal cell carcinoma.

Akamis Bio overview

Akamis Bio, formerly PsiOxus Therapeutics Ltd, develops and discovers novel therapies for the treatment of cancer and other related diseases. The company utilizes T-SIGn, a tumor specific immuno gene platform to develop gene therapies for primary and metastatic solid tumors. Its platform has capabilities to be used in combination with CAR-T and other cell therapies to overcome poor immune cell infiltration, immunosuppressive properties of tumor microenvironment, and systematic toxicity issues. Akamis Bio’s product pipeline includes NG-350A and NG-641 to treat metastatic and advanced epithelial tumors. The company is also investigating NG-347, NG-348, and NG-796A drug programs for application in various cancer treatments. It has an operational presence in the US and the UK. Akamis Bio is headquartered in Abingdon, Oxfordshire, the UK.

For a complete picture of Enadenotucirev’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.